| Literature DB >> 31683523 |
Thaiz Rodrigues Teixeira1, Gustavo Souza Dos Santos2, Lorene Armstrong3, Pio Colepicolo4, Hosana Maria Debonsi5.
Abstract
The marine environment presents a high biodiversity and a valuable source of bioactive compounds with therapeutic and biotechnological potential. Among the organisms present in marine environment, the endophytic fungi isolated from seaweed stand out. These microorganisms have aroused interest in the scientific community regarding its various activities such as antiviral, antimicrobial, antioxidant, photoprotective, cytotoxic, genotoxic, anti-inflammatory, and anticancer, besides establishing important ecological relations with its hosts. Anticancer molecules derived from marine natural sources are a promising target against different types of cancer. The disease's high rates of morbidity and mortality affect millions of people world wild and the search for new therapeutic alternatives is needed. Thus, this review partially summarizes the methodologies for the isolation of seaweed-derived endophytic fungi, as well as describes the anticancer compounds isolated from such microorganisms, reported in the literature from 2009 to the present. In addition, it describes how some biotechnological processes can help in the discovery of bioactive compounds, especially with anticancer activity.Entities:
Keywords: Marine Natural Products; cytotoxicity; endophytic fungi; marine biotechnology; seaweed
Year: 2019 PMID: 31683523 PMCID: PMC6963884 DOI: 10.3390/antibiotics8040205
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Antitumor compounds isolated from seaweed derived-endophytic fungi literature from 2009 to the present. (B) = Brown macroalgae, (G) = Green macroalgae, (R) = Red macroalgae and Rf. = Reference.
| Endophytic Fungi | Sterilization Methods | Host Macroalgae | Compounds | Chemical Class | Cell line/Target Enzyme | Activity (IC50) | Rf |
|---|---|---|---|---|---|---|---|
| - | 7- | steroids | NCI-H460, SW1990, SMMC-7721, HeLa, DU145, HepG2, | 5.00–28.00 µg mL−1 | [ | ||
| (1) Rinsed 3x with sterile sea water; | 6 | terpenoids | H1975, U937, K562, BGC-823, Molt-4, MCF-7, A549, HeLa, HL60, Huh-7 | 1.95–9.40μM | [ | ||
| (1) Rinsed 3x with sterile sea water; | insulicolide B; 14- | terpenoids | ACHN, OS-RC-2, | 0.89–8.20 μM | [ | ||
|
| (1) 15 s 70% EtOH; | Not identified | diorcinol L; ( | ethers | THP-1, A559, Du145 | 7.00–50.00 µg mL−1 | [ |
|
| - | isorhodoptilometrin-1-methyl ether; emodin; 1-methyl emodin;evariquinone; 7-hydroxyemodin-6,8-methyl ether; siderin; arugosin C; variculanol | quinines | Murine L1210, | weak–mild | [ | |
| (1) 15 s 70% EtOH; | asperolides A−C; tetranorditerpenoid derivative; wentilactones A-B; botryosphaerin B; LL-Z1271- | terpenoids | SMMC-7721, HeLa | 10.00–17.00 µM | [ | ||
| (1) 15 s 70% EtOH; | wentilactone B | terpenoids | SMMC-7721, HepG2 | 18.96 µM (SMMC-7721) | [ | ||
| (1) 15 s 70% EtOH; | wentilactone B | terpenoids | SMMC-7721 | - | [ | ||
| (1) 15 s 70% EtOH; | wentilactone A | terpenoids | NCI-H460, NCI-H466 | - | [ | ||
| (1) 15 s 70% EtOH | asperolide A | terpenoids | NCI-H460 | - | [ | ||
| - | (hydroxy(phenyl)methyl)-4H-pyran-4-one; | polyketides | PANC-1, A549 | 8.25 µM - potent on all cells | [ | ||
| (1) 15 s 70% EtOH; | cytoglobosins A-G; isochaetoglobosin D; | alkaloids | A-549, P388, KB | 2.26–10.00 µM | [ | ||
| (1) 15 s 70% EtOH; | cladosporols F−I; cladosporol C; | polyketides | A549, Huh7, LM3, H446 | 1.00–5.00 µM | [ | ||
|
| (1) Rinsed with sterile H2O (3x); | coniosclerodin; ( | polyketides | HTB-9, HLE | 7.20–20.00 µM | [ | |
|
| - | 3-hydroxy-5-(hydroxymethyl)-4-(4’-hydroxy | alkaloids | A-549 | 17.60–61.80% | [ | |
| (1) Washed with | 6, 22-diene-5, 8-epidioxyergosta-3-ol; ergosterol; cyclo-(Tyr-Leu); cyclo-(Phe-Phe); cyclo-(Val-Leu); cyclo-(Phe-Pro); cyclo-(Leu-Ile) | steroids | KB | 10.00–50.00 µg mL−1, | [ | ||
| (1) 15 s 70% EtOH | Not identified (R) | dihydrocarneamide A; iso-notoamide B | alkaloids | NCI-H460 | 55.90–69.30 µmol L−1 | [ | |
| (1) 15 s 70% EtOH | varioloid A; varioloid B | alkaloids | A549, HCT116, HepG2 | 2.50–8.20 µg mL−1 | [ | ||
| (1) 15 s 70% EtOH | penicitides A-B; 2-(2,4-dihydroxy-6-methyl | polyketides | HepG2, NCI-H460, SMMC-7721, SW1990, DU145, Hela, MCF-7 | 32.00–40.00 µg mL−1 | [ | ||
| - | penicisteroids A-B; anicequol; (22 | steroids | HeLa | 15.00–40.00 µg mL−1 | [ | ||
| (1) 15 s 70% EtOH; | chromanone A | chromone | Hepa1c1c7, Cyp1A | 4.00 µg mL−1 | [ | ||
| - | phomaketides A-E; pseurotins A3 and G; FR-111142, pseurotins A, A1, A2, D and F2, 14-norpseurotin A; A-carbonylcarbene; tyrosol; cyclo(-L-Pro-L-Leu); cyclo(-L-Pro-L-Phe) | polyketides | Endothelial progenitor cells (EPCs) | 8.10–19.20 µM | [ | ||
| (1) 15 s 70% EtOH | 8-hydroxyconiothyrinone B; 8,11-dihydroxyconiothyrinone; 4 | quinines | A2780, A2780 CisR | <10.00 µM | [ |
Figure 1Chemical structures of natural products isolated from seaweed derived-endophytic fungi with antitumor potential published from 2009 to 2019.